Category : Study conduct
Title : Birth control measures- women participants.
SOP No. : D 09/07
Date first effective: 01 Jan 2025 **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Category: Study conduct

Title: Birth control measures for women participants.

SOP No: D 09/07 **Total pages:** 05

Date first effective: 01 Jan 2025 **Next Review date:** 31 Dec 2025

Version: 07

Author: Dr. Roopa Parida
DM Resident

Signature with date

Rparida 30/Dec/24

Reviewer: Dr. Mahesh Belhekar
Associate Professor

Dr. Mahesh N. Belhekar
Associate Professor
Department of Clinical Pharmacology
New MS Building, First Floor,
Seth GS Medical College and KEM Hospital
Acharya Donde Marg, Parel,
Mumbai - 400 012. India

Signature with date

Belh 30/Dec/2024

Approved by: Dr. Nithya Gogtay
Professor and Head

Signature with date

30/12/2024

Dr. Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building,
Seth GS Medical College & KEM Hospital
Parel, Mumbai - 400 012.

Category : Study conduct
Title : Birth control measures- women participants.
SOP No. : D 09/07
Date first effective: 01 Jan 2025 **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Table of Contents

Category : Study conduct
Title : Birth control measures- women participants.
SOP No. : D 09/07
Date first effective: 01 Jan 2025 **Review date:** 31 Dec 2025

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

1. Purpose

The purpose of this SOP is to describe the responsibilities of the research team towards counseling of women participants regarding the birth control measures to be adopted during the study period and the procedures to be followed in case a participant is diagnosed to be pregnant during the study period.

2. Scope

This SOP is applicable to all women in reproductive age group who are likely to participate in a clinical trial.

3. Responsibilities

Principal investigator, Co-investigator, Study Coordinator or any other appropriately qualified staff in the team, as delegated by the Principal Investigator, will be responsible for counseling of women participants regarding the birth control measures to be adopted during the study period.

4. Applicable rules, regulations and guidelines

- ICMR's Ethical Guidelines for Biomedical and Health research involving Human Participants, ICMR(2017)
  http://www.icmr.nic.in/guidelines/ICMR_Ethical_Guidelines_2017.pdf
- International Conference on Harmonization, Guidance on Good Clinical Practice
  (ICH GCP) ICH E6 (R3)
  https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf (Adopted on 06 January 2025)
- Indian GCP guidelines 2001
  https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MzM5NQ (Last accessed 20 Dec 2024)
- New Drugs and Clinical Trials 2019
  https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdfdocuments/NewDrugs_CTRules_2019.pdf (Last accessed 20 Dec 2024)

5. Reference to other applicable SOPs

SOP No D 03/07: Responsibilities of the Study Team

SOP No D 15/07: SAE documentation and reporting

6. Detailed instructions

1. During the screening visit, record and document a detailed medical, gynecological and obstetric history of the female participant.
2. Ask the participant regarding use of any birth control measures, present and past; both by self and sexual partner.
3. If yes, document the type of birth control used and advise the participant to continue the same, if the method of contraception is permitted as per the protocol.
4. If not, assess the willingness of the participant to adopt birth control measures recommended in the protocol and offer the available options to the participants e.g. condoms for the male partner and/or oral contraceptives/barrier contraception/intra uterine device (if the protocol permits) to the participant following consultation with a Gynecologist.
5. Gynecology consultation should be sought with the relevant OPD of KEM Hospital as decided by the PI.
6. If the participant is not willing to adopt birth control measures and this is necessary as per the protocol, then she cannot be recruited into the study.
7. It is necessary to emphasize the risk of pregnancy while in the study and its consequences (in the absence of adequate birth control measures).
8. Explain to the participant that a serum and/or urine pregnancy test will be performed at the screening visit and any subsequent visit as per protocol requirements.

9. Ensure that the participant understands the importance about reporting to the study physician in case she misses her menstrual period. In such cases, she should be advised to undergo a pregnancy test and ultrasonography.
10. If pregnancy is confirmed during the trial/study period, refer the participant to the obstetrician of the institute and document and report the same as serious adverse event (SAE) (See SOP D 15/07) and follow the mother throughout the pregnancy period till delivery to monitor the mother's and baby's health status.
11. If the woman is not pregnant, then re-emphasize the importance of preventing a pregnancy during the study and use of a birth control measure.
12. Always follow the instructions in the protocol regarding withdrawal from the study.

Reviewer: Dr. Mahesh Belhekar
Associate Professor

Dr. Mahesh N. Belhekar
Associate Professor
Department of Clinical Pharmacology
New MS Building, First Floor,
GS Medical College and KEM Hospital
Acharya Donde Marg, Parel,
Mumbai - 400 012. India

30/12/2024

Signature with date

Approved by: Dr. Nithya Gogtay
Professor and Head

Signature with date 30/12/24

Dr. Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building,
Seth GS Medical College & KEM Hospital,
Parel, Mumbai - 400 012.